[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenal-incidentaloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenal-incidentaloma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,68,92,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100608337","cardiovascular-complications-after-adrenalectomy-for-pheochromocytoma-and-non-secreting-tumors-100608337",false,"NCT07200245","Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors","Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors - A Prospective Observational Multicenter European Study (HEMODYNAMICS)","HEMODYNAMICS","Inclusion Criteria:\n\n* Patients undergoing adrenalectomy for pheochromocytoma\n* Patients undergoing adrenalectomy for non-secreting tumors. Patients with non-secreting tumors are those with indication for adrenalectomy in the Eurocrine database corresponding to \" excluding malignancy \".\n\nExclusion Criteria:\n\n* Children and minors (\\\u003C18 years).\n* Pregnant women.\n* Patients with other indication for adrenalectomy in Eurocrine (i.e. Adrenocortical cancer, Cushing, Primary aldosteronism, Metastasis).","ALL","18 Years","100 Years",{"count":21,"type":22},522,"ESTIMATED","30 Days","OBSERVATIONAL","Pheochromocytoma is an adrenomedullary chromaffin cell tumour that releases catecholamines. Adverse cardiovascular events are considered the main cause of morbidity and mortality in patients with pheochromocytoma. Consequently, preoperative medical preparations using alpha-blockers or other antihypertensive drugs and the control of hemodynamic instability during adrenalectomy for pheochromocytoma are recommended by guidelines to prevent vasoconstriction, perioperative cardiovascular complications, and the risk of death. However, the definition of a catecholamine-induced hypertensive crisis in patients with pheochromocytoma has only recently been validated by an international consortium as the occurrence of systolic\u002Fdiastolic blood pressure \\>180\u002F120 mmHg1. Limitations of published studies include small sample sizes, and single institution analysis. Some studies have reported substantial variability in the management of pheochromocytomas, with the use of routine preoperative medical preparation varying from 49% to 100%, whereas others have questioned the utility of this preparation for postoperative cardiovascular complications. The aim of this study was to evaluate pan-European practices in terms of specific preoperative medical preparation before surgery and to identify risk factors for postoperative cardiovascular complications 30 days after adrenalectomy for pheochromocytoma and non-secreting tumors (indication for surgery = \" excluding malignancy \").\n\nThe EUROCRINE® registry offers a valuable opportunity to assess clinical practices for preoperative medical preparation and the morbidity linked to adrenalectomy for pheochromocytoma and non-secreting tumors. This prospective study aims to refine surgical protocols and inform updates to existing guidelines, thereby advancing the management of adrenalectomy for pheochromocytoma.",[27,28,29],"Pheochromocytoma","Cardiovascular Complication","Adrenal Incidentaloma","NOT_YET_RECRUITING","2025-09-22",{"date":33,"type":34},"2025-10-01","ACTUAL",{"date":33,"type":22},{"date":37,"type":22},"2027-12-31",{"name":39,"class":40},"Central Hospital, Nancy, France","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100372296","impact-of-adrenal-incidentalomas-and-possible-autonomous-cortisol-secretion-on-cardiovascular-and-metabolic-alterations-100372296","NCT04127552","Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations","Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations (ITACA Study)","ITACA","Inclusion Criteria:\n\n* Incidentally detected adrenal mass\n\nExclusion Criteria:\n\n* Patients with overt Cushing's syndrome, pheochromocytoma, Conn syndrome, adrenocortical carcinoma, late-onset congenital adrenal hyperplasia, adrenal metastasis and adrenal hemorrhage\n* Patients taking medications influencing glucocorticoid production or metabolism\n* Patients with psychiatric diseases or alcohol abuse\n* Pregnancy",true,"80 Years",{"count":52,"type":22},68,"The investigators hypothesize that cardiovascular and metabolic alterations can occur in patients with adrenal adenomas and possible Autonomous Cortisol Secretion (pACS). Investigators hypothesize that adrenalectomy in selected patients, following the 2016 European Congress of Endocrinology (ECE) guidelines, can improve metabolic parameters and cardiovascular risks and features.",[29,55,56],"Hypercortisolism","Adrenal Tumor","RECRUITING","2025-03-24",{"date":60,"type":34},"2025-03-28",{"date":62,"type":34},"2019-01-02",{"date":64,"type":22},"2025-12-31",{"name":66,"class":40},"University of Roma La Sapienza",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":24,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":67},"100556055","crisal-studycancer-risk-in-secreting-adrenal-lesions-100556055","NCT06520111","CRISAL Study:Cancer Risk In Secreting Adrenal Lesions","CRISAL","Inclusion Criteria:\n\n* Patients undergoing elective adrenalectomy;\n* Patients aged ≥ 18 years\n* Acceptance of informed consent\n\nExclusion Criteria:\n\nPatients undergoing emergency adrenalectomy;\n\n* Patients aged ≤ 18 years\n* Pregnant patients",{"count":76,"type":22},300,"12 Months","The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.",[56,29,80],"Surgery",[82,83,84],"cancer risk","adrenal surgery","secreting adrenal lesions","2024-08-27",{"date":87,"type":34},"2024-08-30",{"date":85,"type":22},{"date":90,"type":22},"2024-11-10",{"name":66,"class":40},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":49,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":67},"100466724","performances-on-cognitive-functions-and-brain-function-and-follow-up-after-different-treatments-in-patients-with-autonomous-cortisol-secretion-a-single-center-prospective-observational-study-100466724","NCT05357456","Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study","A Single Center, Prospective, Observational Study to Explore and Evaluate the Differences of Cognitive Function and Brain Function Between Non-functioning Adrenal Adenomas and Autonomous Cortisol Secretion Patients, and the Different Treatments Methods on Cognitive Function and Brain Function in Patients With Autonomous Cortisol Secretion","Inclusion Criteria:\n\n* age 20-65 years;\n* ≥ 6 years of education；\n* right-handed;\n* complete entire cognitive function tests;\n* adrenal lesions ≥ 1 cm in diameter;\n* patients with non-functioning adrenal adenomas;\n* patients with autonomous cortisol secretion.\n\nExclusion Criteria:\n\n* \\\u003C 6 years of education;\n* age \\\u003C 20 years or \\> 65 years;\n* maximum diameter of AI \\\u003C1cm;\n* active malignancies;\n* with a history of thyroid disease;\n* with a history of acute infection in the last month;\n* central nervous system diseases, including brain trauma, intracranial hemorrhage, acute cerebral infarction, etc;\n* contraindications of MRI examination: such as implantation of metal prosthesis in vivo, claustrophobia, etc;\n* adrenal tuberculosis;\n* suspected or diagnosed adrenocortical carcinoma;\n* unable to complete entire cognitive function tests;\n* current use of steroids or any drugs known to alter steroid synthesis or metabolism in the previous 3 months;\n* clinical Cushing syndrome;\n* Cushing disease;\n* primary hyperaldosteronism;\n* pheochromocytoma;\n* severe impairment of heart, liver, kidney and other organs;\n* pregnant and lactating women","20 Years","65 Years",{"count":102,"type":22},62,"This is a single center, prospective, observational study to explore and evaluate the differences on cognitive function and brain function by functional-MRI in autonomous cortisol secretion patients, and the different treatments methods on the cognitive function and brain function in patients with autonomous cortisol secretion",[105,29,106],"Autonomous Cortisol Secretion","Non-functioning Adrenal Adenomas",[108,109,110],"cognitive function","functional MRI","treatment","2022-04-27",{"date":113,"type":34},"2022-05-02",{"date":115,"type":34},"2021-10-01",{"date":117,"type":22},"2026-10-01",{"name":119,"class":40},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":128,"targetDuration":130,"studyType":24,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":67},"100457532","association-between-stroke-and-adrenal-incidentalomas-100457532","NCT05237817","Association Between Stroke and Adrenal Incidentalomas","If Adrenal Incidentalomas Have the Influences to Occur and Progress in Patients With Stroke","ABSAI","Inclusion Criteria:\n\n* stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage.\n\nExclusion Criteria:\n\n* presence of metastatic cancer;\n* AIs smaller than 1 cm;\n* nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts;\n* oral glucocorticoid treatment with more than single doses in the past 3 months;\n* use of inhaled steroids or medication affecting dexamethasone metabolism;\n* systemic estrogen treatment.",{"count":129,"type":22},2,"5 Years","Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.",[133,29],"Stroke",[29,135,133],"Autonomous cortisol secretion","2022-02-08",{"date":138,"type":34},"2022-02-14",{"date":140,"type":34},"2021-04-01",{"date":142,"type":22},"2029-02-28",{"name":144,"class":40},"Xuanwu Hospital, Beijing"]